01
The viral claim comes from one direct comparison
The 2015 trial randomized 100 young men with androgenetic alopecia to rosemary lotion or 2% minoxidil for six months. Participants applied one milliliter twice daily, and standardized microphotographs were taken at baseline, three months and six months.
The rosemary preparation was standardized to a specified 1,8-cineole content. It was not plain rosemary water, kitchen-infused oil or undiluted essential oil. Results from that formulation cannot be transferred automatically to every product carrying the plant name.
02
Both groups changed only at six months
Mean hair count in the rosemary group rose from 122.8 to 129.6, a change of 6.8. In the 2% minoxidil group it rose from 138.4 to 140.7, a change of 2.3. Both within-group changes were reported as statistically significant at six months; neither group changed significantly at month three.
The standard deviations were large—roughly 38 to 51 hairs—and the paper did not report the size of the counting area in the way modern target-area trials usually do. The absolute numbers therefore need more context than a social-media headline provides.
03
No significant difference does not prove equivalence
The study found no statistically significant difference between groups. That is not the same as demonstrating that the treatments are equivalent. An equivalence or noninferiority trial needs a prespecified margin and enough statistical power to rule out a clinically important difference.
There was also no placebo or vehicle group, so the study cannot separate treatment effects from measurement variation, massage, natural cycling or regression toward the mean. The comparator was 2% minoxidil, not the better-supported 5% male formulation.
04
One trial is a research lead, not a replacement claim
Itching increased in both groups, and the report contains inconsistencies about which group experienced more. Essential oils can irritate skin, and concentrated products should not be treated as automatically gentle because they are botanical.
The fair conclusion is that a standardized rosemary lotion deserves independent placebo-controlled replication. The available trial does not justify telling readers to replace a supported therapy, use an undiluted essential oil or expect regrowth without first identifying the cause of hair loss.
Direct sources
Read the research
- Panahi et al. — Rosemary oil versus minoxidil 2% in androgenetic alopecia ↗SKINmed (2015), PMID 25842469; randomized comparative trial
- Primary SKINmed issue containing the full trial report ↗SKINmed volume 13, issue 1, pages 15–21; full methods and reported tables
- Olsen et al. — Placebo-controlled trial of 5% and 2% topical minoxidil ↗Comparator context from a separate 48-week RCT, PMID 12196747, DOI 10.1067/mjd.2002.124088
- NIH DailyMed — Minoxidil topical solution label ↗Official labeling context for indications, warnings and continued use
Editorial transparency
This article was prepared by the HairstyleChange Research Desk from the cited sources. It has not been presented as medical review by a named clinician. Corrections and qualified reviewer enquiries are welcome through our contact page.
How we research and correct articles ↗